Baxter Gains FDA Clearance for Bone Graft Substitute

Baxter International was granted FDA 510(k) clearance to market Actifuse Flow bone graft substitute, offered in a prepackaged delivery syringe for precise placement into small bony voids or gaps.

U.S. launch is expected by 4Q18, and Actifuse Flow will be sold in 1.5-, 3- and 5-mL sizes. The product has application in a variety of orthopaedic...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0